SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ebola Outbreak 2014 - News, Updates and Related Investments
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sense who wrote (528)11/5/2014 8:33:06 AM
From: IRWIN JAMES FRANKEL  Read Replies (2) of 608
 
>>Reality is that ebola is a biohazard level IV risk... and that isn't going to change...

True. But there is no way we are going to implement BSL-4 in treating ZEBOV patients. That has not been done so far and we will not do it. It is not practical. CDC will set the rules and change them as they see fit.

There is no doubt that the impact on ICU space of treating ZEBOV will be big if the number of cases in the US ramp. That will be managed by concentrating cases in specified hospitals.

And the ramp is likely if Ebola keeps growing rapidly in Africa and we do not close our borders to people returning.

Given the reaction of our population, and politicians willingness to follow the herd, there likely will be more restrictions to people coming into the US from impacted areas.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News